NCT00416624 · FLOW

Participant flow

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)
id
FG000
title
Epoetin Alfa - 40k Weekly
description
Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
id
FG001
title
Epoetin Alfa - 80k Every 3 Weeks
description
Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
id
FG002
title
Epoetin Alfa - 120k Every 3 Weeks
description
Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)
id
FG003
title
Darbepoetin Alfa - 500 mcg Every 3 Weeks

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
1
group Id
FG001
num Subjects
6
group Id
FG002
num Subjects
4
group Id
FG003
num Subjects
9
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
4
group Id
FG001
num Subjects
7
group Id
FG002
num Subjects
7
group Id
FG003
num Subjects
1
type
Death
reasons
group Id
FG000
num Subjects
8
group Id
FG001
num Subjects
3
group Id
FG002
num Subjects
2
group Id
FG003
num Subjects
2
type
Adverse Event
reasons
group Id
FG000
num Subjects
8
group Id
FG001
num Subjects
11
group Id
FG002
num Subjects
5
group Id
FG003
num Subjects
5
type
Other
reasons
group Id
FG000
num Subjects
1
group Id
FG001
num Subjects
0
group Id
FG002
num Subjects
0
group Id
FG003
num Subjects
0
type
Cancel
milestones
achievements
group Id
FG000
num Subjects
61
group Id
FG001
num Subjects
60
group Id
FG002
num Subjects
58
group Id
FG003
num Subjects
57
type
STARTED
achievements
group Id
FG000
num Subjects
39
group Id
FG001
num Subjects
33
group Id
FG002
num Subjects
40
group Id
FG003
num Subjects
40
type
COMPLETED
achievements
group Id
FG000
num Subjects
22
group Id
FG001
num Subjects
27
group Id
FG002
num Subjects
18
group Id
FG003
num Subjects
17
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

There were two canceled participants and 1 ineligible participants prior to study medication begins. These three participants were excluded from all analysis.

recruitment Details

Two hundred and thirty-nine (239) participants were enrolled at 10 Mayo Clinic Cancer Research Consortium (MCCRC) sites between February 2007 and December 2008.

Complete source fields